Schaeffler improves profitability in first half of 2026

Schaeffler AG reported first-half 2026 results. Revenue was 11,667 million euros, flat vs 11,845 million euros prior year. EBIT before special items rose to 549 million euros (482 million). EBIT margin before special items was 4.7% (4.1%). Free cash flow before M&A was -300 million euros. Full-year guidance was confirmed: revenue 22.5-24.5 billion euros and EBIT margin 3.5-5.5%.

Original reporting
Published Aug 17, 2026, 1:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 1:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Schaeffler improves profitability in first half of 2026 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The report combines flat revenue with improved operating profitability (EBIT margin before special items) and a confirmed 2026 guidance range, while also disclosing negative free cash flow and higher net debt. This mix can drive near-term repricing toward earnings quality, but with caution on cash and leverage.

02

Market read

Traders can update expectations for 2026 profitability and cash generation based on the disclosed 1H margins, segment trends, and the reiterated guidance ranges.

03

What to watch

Net financial debt increased to 5,545 million euros and free cash flow before M&A was -300 million euros, which may raise concerns about balance-sheet risk even with guidance confirmed.

Relevance 8/10Novelty 7/10Timing: published today with 1H 2026 interim results and 2026 guidance confirmation

Background

Schaeffler AG released its interim financial report for the first half of 2026, covering group and division performance and reiterating full-year outlook.

Market effects

Signals resilience in motion technology demand pockets (notably E-Mobility and Bearings/Industrial) despite weak ICE conditions, which can influence sentiment across auto-supply peers.

Highlights regional divergence: Asia/Pacific and the Americas grew at constant currency while Greater China declined, relevant for regional demand expectations.

Reinforces the broader auto-supply theme of margin management and selective capex toward growth areas like humanoid robotics and defense.

Counterpoint

The headline profitability improvement may be partly offset by cash strain and rising leverage, so equity upside could be capped if investors prioritize cash conversion.

Key entities

  • Schaeffler AG

    Motion technology group reporting 1H 2026 interim results, segment performance, and confirmed 2026 guidance.

  • Klaus Rosenfeld

    CEO quoted confirming full-year guidance and citing progress in humanoid robotics and defense.

  • Christophe Hannequin

    CFO quoted on operating performance focus, capex direction, and inventory management to improve free cash flow.

Related articles

MedAI 8/10

Schaeffler Q3 2026 slides: EUR 240mn cleanup, humanoid growth

Schaeffler AG reported Q3 2026 results within guidance, with sales of EUR 5.8B and an EBIT margin of 4.2%. The company announced EUR 240M in one-off charges for E-Mobility restructuring and highlighted growth in humanoid robotics, with an order book of EUR 400M. Shares fell 1.02% to $5.83. Management confirmed full-year 2026 and mid-term 2028 targets despite market challenges.

Med

Why is Schaeffler stock sliding today?

Schaeffler stock fell 3.7% to €5.73 after reporting €240M in special charges in its E-Mobility division. Nine-month revenue declined to €17.5B, while Q3 EBIT margin slipped 0.3% YoY. Despite improved free cash flow and confirmed guidance, shares hit a 52-week low due to EV transition concerns.

$JNJMedAI 8/10

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

Johnson & Johnson (JNJ) stock fell 5% despite raising its full-year outlook due to one-time charges, including talc litigation. Q3 2026 revenue grew 5.9%, but reported net earnings dropped 95.9%. Eli Lilly (LLY) and Pfizer (PFE) also saw declines. JNJ's growth came from its Innovative Medicine division, while MedTech lagged. The company secured market authorization for its OTTAVA robotic surgical system and priority review for RYBREVANT FASPRO.